AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20070299 — intervention group
Group type: COMPARATOR
Intervention: Control group (6-week induction cycle only)
Number of subjects: 482
Study 20070299 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance regimen with monthly instillations for 1 year
Number of subjects: 482
Study 17445330 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention for providers and CBD agents
Number of subjects: 45
Study 17445330 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailing intervention
Number of subjects: 45
Study 17445330 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (DMPA)
Number of subjects: 45
Study 17445330 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-based activities with concurrent demand creation activities
Number of subjects: 45
Study 16199428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 28
Study 16199428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle)
Number of subjects: 28
Study 16199428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of rosiglitazone and EE/CPA
Number of subjects: 28
Study 12955342 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative therapy for mild incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy for moderate incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 2 years for mild incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: COMPARATOR
Intervention: Follow-up at 2 years for moderate incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders for mild incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: COMPARATOR
Intervention: Responders for moderate incontinence
Number of subjects: 150
Study 12955342 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life improvements
Number of subjects: 150
Study 10875168 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizzes for previewing frequently asked questions (FAQ)
Number of subjects: 0
Study 10875168 — intervention group
Group type: COMPARATOR
Intervention: Quizzes for previewing chapter outlines
Number of subjects: 0
Study 9537132 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autograft
Number of subjects: 59
Study 9537132 — intervention group
Group type: COMPARATOR
Intervention: Topical mitomycin C (0.2 mg/ml, 0.02%)
Number of subjects: 59
Study 8182273 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated, alum‐adjuvanted hepatitis A vaccine (VAQTA)
Number of subjects: 0
Study 3802604 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg
Number of subjects: 60
Study 3802604 — intervention group
Group type: COMPARATOR
Intervention: Sublingual isosorbide dinitrate (ISDN) 5 mg
Number of subjects: 60
Study 31238172 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS Plus intervention providing family caregivers with support via education, referrals, and problem-solving techniques over 12 months, delivered on-site by existing ADS staff.
Number of subjects: 50
Study 31238172 — intervention group
Group type: COMPARATOR
Intervention: Standard Adult Day Services (ADS) without the embedded caregiver support program.
Number of subjects: 50
Study 28468077 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitai tablet
Number of subjects: 0
Study 28468077 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitai tablet plus buprenorphine
Number of subjects: 0
Study 28468077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26667089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick test results (negative/equivocal, 1+, ≥2+)
Number of subjects: 1033
Study 26667089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick test results (1+) in normotensive women
Number of subjects: 1033
Study 26667089 — intervention group
Group type: EXPERIMENTAL
Intervention: P/Cr test
Number of subjects: 1033
Study 26667089 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum urine samples
Number of subjects: 1033
Study 23774044 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial treatment in the masseter and temporalis muscles
Number of subjects: 48
Study 23774044 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 48
Study 21619574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training (3-5 sessions per week, session duration minimum 50 minutes)
Number of subjects: 0
Study 21619574 — intervention group
Group type: COMPARATOR
Intervention: Standard training (3-5 sessions per week, session duration maximum 25 minutes)
Number of subjects: 0
Study 19808138 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of levofloxacin 500 mg
Number of subjects: 26
Study 19808138 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of levofloxacin 500 mg
Number of subjects: 26
Study 19808138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 26
Study 17034283 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunzhi-Danshen capsules (3.6 g Yunzhi and 1.4 g Dangshem daily for 16 weeks)
Number of subjects: 27
Study 17034283 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 capsules daily for 16 weeks)
Number of subjects: 27
Study 17034283 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunzhi-Danshen capsules
Number of subjects: 27
Study 17034283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15073259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg rhTSH
Number of subjects: 36
Study 15073259 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg rhTSH
Number of subjects: 36
Study 15073259 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no rhTSH pretreatment)
Number of subjects: 36
Study 11180306 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced designs using covariates
Number of subjects: 0
Study 11180306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imbalance measure
Number of subjects: 0
Study 11180306 — intervention group
Group type: EXPERIMENTAL
Intervention: Random selection method from balanced designs
Number of subjects: 0
Study 9416454 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 47
Study 8332693 — intervention group
Group type: EXPERIMENTAL
Intervention: Scamper technique
Number of subjects: 52
Study 8332693 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 52
Study 2945811 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (0.2 g)
Number of subjects: 6
Study 2945811 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (1 g)
Number of subjects: 6
Study 28805281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and Caffeine 100 mg
Number of subjects: 562
Study 28805281 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 562
Study 28805281 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 562
Study 28805281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Anxiety and Depression)
Number of subjects: 915
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression only group
Number of subjects: 915
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 915
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing symptoms
Number of subjects: 915
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 915
Study 27624487 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 915
Study 24837773 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of MMR at 8 months
Number of subjects: 280
Study 24837773 — intervention group
Group type: EXPERIMENTAL
Intervention: First dose of MMR at 12 months
Number of subjects: 280
Study 24837773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after first dose of MMR
Number of subjects: 280
Study 24837773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after second dose of MMR
Number of subjects: 280
Study 22257994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based skin preparation solution
Number of subjects: 20
Study 22257994 — intervention group
Group type: COMPARATOR
Intervention: Iodine-based skin preparation solution
Number of subjects: 20
Study 20483888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (early group)
Number of subjects: 42
Study 20483888 — intervention group
Group type: COMPARATOR
Intervention: Electronic metronome without therapy but limited support (5-10 minutes instruction and on-demand telephone assistance) for four weeks (late group)
Number of subjects: 42
Study 17922612 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 133
Study 17922612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 16002204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) program, initiated before discharge, consisting of Kegel exercises.
Number of subjects: 300
Study 16002204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal instruction in PFMT).
Number of subjects: 300
Study 16002204 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both groups).
Number of subjects: 300
Study 11792137 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban + heparin
Number of subjects: 1915
Study 11792137 — intervention group
Group type: COMPARATOR
Intervention: heparin alone
Number of subjects: 1915
Study 11792137 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 1915
Study 10367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1600 microg/d for 21 days)
Number of subjects: 188
Study 10367823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to budesonide, for 21 days)
Number of subjects: 188
Study 10367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 188
Study 7739681 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b given subcutaneously three times a week for 18 months (group 1)
Number of subjects: 303
Study 7739681 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 million units of interferon alfa-2b three times a week for 12 months (group 2)
Number of subjects: 303
Study 7739681 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (group 3)
Number of subjects: 303
Study 7739681 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of interferon alfa-2b given three times a week for 18 months (group 1)
Number of subjects: 303
Study 2199866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (2 g intravenously)
Number of subjects: 377
Study 2199866 — intervention group
Group type: COMPARATOR
Intervention: Cefotetan (2 g intravenously)
Number of subjects: 377
Study 7028047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine cream
Number of subjects: 0
Study 7028047 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 0
Study 30887679 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic partial nephrectomy (RAPN)
Number of subjects: 142
Study 30887679 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic partial nephrectomy (LPN)
Number of subjects: 142
Study 30887679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RAPN and LPN
Number of subjects: 142
Study 30343592 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURBT
Number of subjects: 160
Study 30343592 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 160
Study 26325026 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniPlus method with dynamic balance training (20 cognitive training sessions twice per week for 10 weeks)
Number of subjects: 80
Study 26325026 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniPlus method with dynamic balance training
Number of subjects: 80
Study 26325026 — intervention group
Group type: COMPARATOR
Intervention: Balance training alone (same duration and frequency as experimental group)
Number of subjects: 80
Study 26905701 — intervention group
Group type: EXPERIMENTAL
Intervention: High incision at upper part of lower segment
Number of subjects: 200
Study 26905701 — intervention group
Group type: COMPARATOR
Intervention: Traditional lower segment incision
Number of subjects: 200
Study 21457353 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone (AB) chips
Number of subjects: 92
Study 21457353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossix membrane (OM)
Number of subjects: 92
Study 21457353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AB chips and OM
Number of subjects: 92
Study 21457353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 20649896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid warmed using a warming cabinet for at least 8 hours
Number of subjects: 76
Study 20649896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid warmed using an in-line warming device
Number of subjects: 76
Study 20649896 — intervention group
Group type: COMPARATOR
Intervention: Fluid at room temperature
Number of subjects: 76
Study 17666481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 339
Study 17666481 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 339
Study 15033676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 60
Study 15033676 — intervention group
Group type: COMPARATOR
Intervention: Non-5-FU chemotherapy (cis/carboplatin, anthracycline, cyclophosphamide)
Number of subjects: 60
Study 15033676 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) with glyceroltrinitrate pre-treatment
Number of subjects: 60
Study 15033676 — intervention group
Group type: COMPARATOR
Intervention: Non-5-FU chemotherapy
Number of subjects: 60
Study 11839841 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 0
Study 11839841 — intervention group
Group type: COMPARATOR
Intervention: MRI metrics (new enhancing lesions, percentage change of T2 lesion volume, composite MRI score)
Number of subjects: 0
Study 10424691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity noise deviant
Number of subjects: 0
Study 10424691 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced noise intensity
Number of subjects: 0
Study 7749824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.4 g daily)
Number of subjects: 33
Study 7749824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil with vitamin E (2.4 g daily)
Number of subjects: 33
Study 2261209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Idarubicin
Number of subjects: 10
Study 2261209 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Idarubicin under non-fasting conditions
Number of subjects: 10
Study 2261209 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicinol (metabolite)
Number of subjects: 10
Study 376027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal perfusion method
Number of subjects: 40
Study 376027 — intervention group
Group type: COMPARATOR
Intervention: Standard method (not explicitly mentioned)
Number of subjects: 40
Study 31068015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive chronotype-based bright light therapy (30 minutes a day for 3 weeks, illuminance: 4246 lux, irradiance: 1802.81 µW.cm‐2)
Number of subjects: 0
Study 31068015 — intervention group
Group type: COMPARATOR
Intervention: Control group with multimodal psychiatric treatment
Number of subjects: 0
Study 28374211 — intervention group
Group type: EXPERIMENTAL
Intervention: FITNET (Facebook-based physical activity intervention)
Number of subjects: 85
Study 28374211 — intervention group
Group type: COMPARATOR
Intervention: SC (self-help comparison condition)
Number of subjects: 85
Study 28374211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 25823522 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed universal donor (UD) plasma
Number of subjects: 680
Study 25823522 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group A plasma
Number of subjects: 680
Study 25823522 — intervention group
Group type: COMPARATOR
Intervention: Thawed AB plasma
Number of subjects: 680
Study 24022799 — intervention group
Group type: EXPERIMENTAL
Intervention: Misleading narrative
Number of subjects: 93
Study 24022799 — intervention group
Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 93
Study 24022799 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed test (2 weeks after viewing)
Number of subjects: 93
Study 24022799 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of greater distress
Number of subjects: 93
Study 21872473 — intervention group
Group type: EXPERIMENTAL
Intervention: High custom made orthopaedic shoe
Number of subjects: 19
Study 21872473 — intervention group
Group type: COMPARATOR
Intervention: Normal shoes
Number of subjects: 19
Study 18832520 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (OD) 3 g mesalazine granules
Number of subjects: 380
Study 18832520 — intervention group
Group type: COMPARATOR
Intervention: Three times daily (TID) 1 g mesalazine granules
Number of subjects: 380
Study 18832520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OD and TID groups
Number of subjects: 380
Study 17904962 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus azithromycin every 4 months
Number of subjects: 124
Study 17904962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 14739800 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 150 mmHg
Number of subjects: 46
Study 14739800 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen administration adjusted to arterial oxygen tensions of approximately 300 mmHg
Number of subjects: 46
Study 14739800 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative tissue oxygen measurement adjacent to the wound
Number of subjects: 46
Study 14739800 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative tissue oxygen measurement in the upper arm
Number of subjects: 46
Study 14739800 — intervention group
Group type: EXPERIMENTAL
Intervention: First postoperative morning measurements
Number of subjects: 46
Study 15848976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum in addition to oral health education (Group G)
Number of subjects: 1342
Study 15848976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education (Group E)
Number of subjects: 1342
Study 15848976 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 1342
Study 10511361 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 60
Study 10511361 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ritodrine
Number of subjects: 60
Study 7867351 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic patients
Number of subjects: 17
Study 7867351 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 1959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 185
Study 1959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 185
Study 1959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg and 10 mg twice daily
Number of subjects: 185
Study 1959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 2.5 mg, 5 mg, 10 mg twice daily
Number of subjects: 185
Study 1959195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 2.5 mg and 5 mg twice daily
Number of subjects: 185
Study 1959195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 7048037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 200
Study 7048037 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 200
Study 30383184 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (20 mg/kg every 4 weeks) + tremelimumab (1 mg/kg every 4 weeks for 4 cycles, followed by durvalumab (10 mg/kg every 2 weeks))
Number of subjects: 267
Study 30383184 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg every 2 weeks) monotherapy
Number of subjects: 267
Study 30383184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg every 4 weeks for 7 doses then every 12 weeks for 2 doses) monotherapy
Number of subjects: 267
Study 25400009 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL MAL‐PDT
Number of subjects: 33
Study 25400009 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 33
Study 23612222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic exercise intervention (10 weeks, 2 supervised and 1 home-based session per week)
Number of subjects: 30
Study 23612222 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 21208264 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR skills testing during the final half-hour of the course
Number of subjects: 146
Study 21208264 — intervention group
Group type: COMPARATOR
Intervention: Additional training (control group)
Number of subjects: 146
Study 21208264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol increase measured pre-course, half an hour before the end of the course, and post-course
Number of subjects: 146
Study 19752423 — intervention group
Group type: EXPERIMENTAL
Intervention: AREDS 9-step severity scale
Number of subjects: 1001
Study 17604473 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (100 mg/kg single oral dose)
Number of subjects: 60
Study 17604473 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 60